BioCentury

12:39 AM GMT, Feb 1, 2018
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Non-adherence policy

Having worked out how to make non-adherent primary cells amenable to microscopy, Allcyte GmbH has created a platform for imaging interactions between T cells and B cells that can predict drug responses in hematological cancers.

COO Nikolaus Krall said Allcyte’s approach of studying drug responses in both cancer and immune cells provides more accurate predictions of responses than methods that rely solely on cell lines or primary cancer

Read the full 685 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.